Replies to post #14600 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

As I've said b4 the buck stops with the CEO. IF you have paid any attention to those webcasts like I have what you will observe is an overbearing insecure CEO who wants the spotlight on himself at all times. Doc Williams did what he was told to do AND in many of those webcasts he deferred answers to questions he obviously knew back over to the CEO to ramble about in whatever way he saw fit. Also, open your eyes. Look at where Doc Williams is now. Do you think he's doing better or worse now? He IS the guy we needed at AP. Here is the bio for Doc Williams and the CEO of their company prior to the official buyout of Marvel Biotechnologies Inc - 2 months ago:

Proposed directors and officers of the resulting issuer

On completion of the proposed transaction, the directors and officers of AVC are expected to resign, other than Joanne Yan, who is expected to remain a director, and the following board of directors and management team are expected to be appointed:

Mr. Matheson, chief executive officer and director

Mr. Matheson has spent over 35 years of his career in the investment and capital markets industries and is an experienced and seasoned senior executive in diverse areas of finance, capital markets, entrepreneurship and investing. Among his accomplishments are multiple financings in excess of $1-billion of both public and private companies in the biotechnology, technology, mining, oil and gas industries as well as numerous venture start-ups. Mr. Matheson began his career at Wood Gundy in 1983 becoming vice-president and director. He left Wood Gundy in 1995 to spearhead the Calgary operations of Canaccord Capital Corp. and after several years moved to Bolder Investment Partners, starting up its Calgary operations. In 2010, Bolder merged and Mr. Matheson and his colleagues moved to other independent investment firms concluding with Aligned Capital Partners Inc. until late 2019. A significant amount of Mr. Matheson’s career has been spent in capital markets advisory and risk management services to companies and industries that require his expertise. In late 2019, Mr. Matheson commenced the operation of Renaissance Mercantile Corp., a privately owned merchant bank where he is executive chairman and is a shareholder of Marvel Biotechnology Inc.

Mr. Matheson currently provides services as the president and chief executive officer of Marvel pursuant to an executive management and administrative services agreement from Renaissance Mercantile Corp.

Dr. Mark Williams, president, chief science officer and director

Dr. Williams is chief scientific officer of Marvel and has 15 years of experience in drug and medical device development having repurposed three drugs from preclinical studies directly to positive phase 2 data, including manufacturing and toxicology. Dr. Williams is the author of more than 12 patents and an inventor of DM199 (a recombinant protein) in phase 2 trials for stroke and kidney disease. Dr. Williams is also involved in the financing and collaboration/partnership side of life science companies, having assisted to secure arrangements with drug foundations, pharma companies and various government agencies including Health Canada and U.S. FDA.

Dr. Williams has a master in business administration from the University of Manitoba and a PhD from the University of Alberta.

https://marvelbiotechnology.com/news/

Full stop

Guess what? The bio above for Doc Williams does not include any work he's accredited for at Algernon Pharmaceuticals. Including the 16 pending patents currently in the hopper for all of Algernon's existing pipeline. Which also has yet to show pending patents for COVID-19 and DMT. So the list will get even longer down the road - as Christopher Moreau has claimed Algernon still collaborates with Doc Williams during this time frame of uncertainty. A time frame which Christopher Moreau had the opportunity to explain in detail in the Biopub webcast why Doc Williams left Algernon Pharmaceuticals. Moreau asked KSS to ask him the question and KSS did not and pivoted to something else. Maybe the Biopub gang was given a detailed reason why he left before or after the Biopub webcast? Either way Doc Williams is doing just swell. From what my eyes can see he got a major upgrade! Due was playing chess and Team Cobra is still playing checkers with our pennies. I will not be surprised If/When Marvel Biotechnologies market cap surpasses that of AP in due time. Those guys are cut from a different cloth.

Different cloth:

Christopher J. Moreau, Chief Executive Officer

Mr. Moreau is a seasoned business professional in the life sciences sector with a strong background in biotechnology research, business development and a deep expertise in the capital markets. Mr. Moreau was previously President & CEO and Director of a publicly traded company focussed on the research & development of screening tests for prostate cancer, skin cholesterol and type 2 diabetes. He has raised in excess of $30 million from the capital markets and has over 30 years of senior management experience in private & publicly traded company environments.

Christopher Bryan, PhD, Vice President Research & Operations

Dr. Christopher Bryan graduated from the University of Toronto, with a PhD in organic chemistry and brings significant skills and experience to Algernon. His background as a scientist and senior manager includes the synthesis of hundreds of novel small molecules as potential therapeutic agents, the coordination of regional commercial teams and internal departments (i.e., marketing, R&D, manufacturing, sales and regulatory affairs), and the management of multiple strategic relationships including those involving key opinion leaders. He also has extensive experience in scientific writing, data analysis and literature review.

Full stop

Anybody know if the CEO of AP has a college degree?

Surely, it's not everything but everybody can't be Bill Gates (college dropout) either.

@ Linkedin



Thank you. I'm moving onto Nash Pharmaceuticals now...

M$